1. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis;Winearls, C.G.; Oliver, D.O.; Pippard, M.J.; Reid, C.; Downing, M.R.; Cotes, P.M.;Lancet,1986
2. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin;Eschbach, J.W.; Egrie, J.C.; Downing, M.R.; Browne, J.K.; Adamson, J.W.;N Engl J Med,1987
3. Recombinant human erythropoietin therapy in haemodialysis patients - dose determination and clinical experience;Bommer, J.; Alexiou, U.; Muller-Buhl, E.; Eifert, J.; Ritz, E.;Nephrol Dial Transpl,1987
4. Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis;Casati, S.; Passerini, P.; Campise, M.R.;Br Med J,1987
5. Recombinant human erythropoietin treatment in pre-dialysis patients: a double-blind placebo-controlled trial;Lim, V.S.; DeGowin, R.L.; Zavaba, D.;Ann Intern Med,1989